Abstract
Coronavirus Numerous coronavirus disease 2019 (COVID-19) vaccines are under development in clinical trials, but what do we need to know to ensure that they are used correctly? There are two vaccination strategies: direct protection of vulnerable populations and vaccination of the general population to indirectly protect those at highest risk of severe disease. In a Perspective, Lipsitch and Dean outline the important features of vaccine responses, particularly efficacy in high-risk groups and reduction of infectiousness. These end points are not routinely examined in phase 3 trials, so it is important to develop trials and subsequent studies to assess how vaccines perform so that they can be used optimally. Science , this issue p. [763][1] [1]: /lookup/doi/10.1126/science.abe5938
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
